A Phase 3 Multi-center Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy

Brief description of study

The purpose of this research is to study whether an investigational drug, called ampreloxetine, works and how safe it is when taken over several months to treat symptomatic neurogenic orthostatic hypotension (nOH) in people with multiple system atrophy (MSA). It will also look at the effects of ampreloxetine on general well-being and if it can improve symptoms of nOH.

Clinical Study Identifier: s23-00335

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.